https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/660767/takeda-s-plump-gv-s-yeshwant-announce-retirement-planshttps://www.biocentury.com/article/660767/takeda-s-plump-gv-s-yeshwant-announce-retirement-plans?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSTAKEDA’S PLUMP, GV’S YESHWANT ANNOUNCE RETIREMENT PLANSAndy Plump has helped remake Japanese pharma an innovative global playerFri, 11 Sep 2026 17:58:49 -0700https://www.biocentury.com/article/660775/with-deep-pockets-solstice-takes-next-gen-ctla-4-into-neoadjuvant-treatmenthttps://www.biocentury.com/article/660775/with-deep-pockets-solstice-takes-next-gen-ctla-4-into-neoadjuvant-treatment?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEWITH DEEP POCKETS, SOLSTICE TAKES NEXT-GEN CTLA-4 INTO NEOADJUVANT TREATMENTRA Capital-led syndicate backing NewCo with $225M, in-licensed assetFri, 11 Sep 2026 17:19:05 -0700https://www.biocentury.com/article/660765/encoded-preps-for-dravet-launch-with-275m-round-finance-reporthttps://www.biocentury.com/article/660765/encoded-preps-for-dravet-launch-with-275m-round-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEENCODED PREPS FOR DRAVET LAUNCH WITH $275M ROUND: FINANCE REPORTPlus: NewCo Solstice’s $225M round; newly public Yarrow draws a follow-on; and moreFri, 11 Sep 2026 16:00:05 -0700https://www.biocentury.com/article/660771/letter-from-the-editor-fih-data-is-now-the-time-for-changehttps://www.biocentury.com/article/660771/letter-from-the-editor-fih-data-is-now-the-time-for-change?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYLETTER FROM THE EDITOR: FIH DATA — IS NOW THE TIME FOR CHANGE?Back to School 2026: The bold risks required to overhaul first-in-human trialsFri, 11 Sep 2026 15:52:56 -0700https://www.biocentury.com/article/660728/novartis-dm1-miss-raises-stakes-for-next-wave-of-dmpk-readoutshttps://www.biocentury.com/article/660728/novartis-dm1-miss-raises-stakes-for-next-wave-of-dmpk-readouts?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTNOVARTIS DM1 MISS RAISES STAKES FOR NEXT WAVE OF DMPK READOUTSFour upcoming readouts will test the translational potential of additional DM1 candidates as the field awaits full results from Novartis’ HARBOR trialThu, 10 Sep 2026 16:45:26 -0700https://www.biocentury.com/article/660707/biotech-s-2026-ipos-deliver-broad-gains-through-augusthttps://www.biocentury.com/article/660707/biotech-s-2026-ipos-deliver-broad-gains-through-august?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEBIOTECH’S 2026 IPOS DELIVER BROAD GAINS THROUGH AUGUST18 of 21 are trading above their IPO priceThu, 10 Sep 2026 16:40:26 -0700https://www.biocentury.com/article/660756/science-spotlight-multiple-sclerosis-genetics-point-inside-the-brainhttps://www.biocentury.com/article/660756/science-spotlight-multiple-sclerosis-genetics-point-inside-the-brain?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: MULTIPLE SCLEROSIS GENETICS POINT INSIDE THE BRAINBioCentury's translational roundup also includes a first-trimester biomarker for preeclampsia and a programmable degrader for pathogenic β-cateninThu, 10 Sep 2026 14:51:26 -0700https://www.biocentury.com/article/660726/novartis-growth-drivers-beyond-the-setbackshttps://www.biocentury.com/article/660726/novartis-growth-drivers-beyond-the-setbacks?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTNOVARTIS’ GROWTH DRIVERS, BEYOND THE SETBACKSFrom assets against BTK to BAFF-R, Swiss pharma looking ahead to other pipeline inflection points Thu, 10 Sep 2026 11:52:25 -0700https://www.biocentury.com/article/660751/michael-davis-a-firm-hand-on-cder-s-tillerhttps://www.biocentury.com/article/660751/michael-davis-a-firm-hand-on-cder-s-tiller?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMICHAEL DAVIS: A FIRM HAND ON CDER’S TILLERIn his first interview as CDER Director, Davis expresses respect for staff, patient focus, deep knowledge of psychedelicsWed, 09 Sep 2026 18:23:09 -0700https://www.biocentury.com/article/660704/brainchild-bringing-car-ts-directly-to-the-brainhttps://www.biocentury.com/article/660704/brainchild-bringing-car-ts-directly-to-the-brain?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEBRAINCHILD: BRINGING CAR TS DIRECTLY TO THE BRAINRepeat dosing into the CSF is designed to sidestep the toxicities that have limited CNS-directed cell therapiesWed, 09 Sep 2026 17:05:07 -0700https://www.biocentury.com/article/660709/arpa-h-envisions-faster-rare-disease-diagnosis-with-aihttps://www.biocentury.com/article/660709/arpa-h-envisions-faster-rare-disease-diagnosis-with-ai?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTARPA-H ENVISIONS FASTER RARE DISEASE DIAGNOSIS WITH AIAgency backs four projects to develop early detection tools in Rare Disease AI/ML for Precision Integrated Diagnostics programWed, 09 Sep 2026 16:10:06 -0700https://www.biocentury.com/article/660738/the-factors-that-could-have-contributed-to-novartis-lp-a-misshttps://www.biocentury.com/article/660738/the-factors-that-could-have-contributed-to-novartis-lp-a-miss?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTHE FACTORS THAT COULD HAVE CONTRIBUTED TO NOVARTIS’ LP(A) MISSAntisense therapy pelacarsen from Novartis failed to improve cardiovascular outcomes in Phase IIITue, 08 Sep 2026 18:32:29 -0700https://www.biocentury.com/article/660746/novartis-phase-iii-misses-pharma-deals-analysis-mfn-carve-outs-a-biocentury-podcasthttps://www.biocentury.com/article/660746/novartis-phase-iii-misses-pharma-deals-analysis-mfn-carve-outs-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTNOVARTIS’ PHASE III MISSES, PHARMA DEALS ANALYSIS, MFN CARVE-OUTS — A BIOCENTURY PODCASTPlus: A tribute to Peter Barton Hutt, who helped shape drug law for decadesTue, 08 Sep 2026 18:07:37 -0700https://www.biocentury.com/article/660735/novartis-phase-iii-misses-compound-novo-s-cardiovascular-setbackhttps://www.biocentury.com/article/660735/novartis-phase-iii-misses-compound-novo-s-cardiovascular-setback?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTNOVARTIS’ PHASE III MISSES COMPOUND NOVO’S CARDIOVASCULAR SETBACKBioCentury’s Clinical Report, Sept. 4-8Tue, 08 Sep 2026 18:03:47 -0700https://www.biocentury.com/article/660741/making-center-directors-permanent-latest-signal-of-stability-for-fdahttps://www.biocentury.com/article/660741/making-center-directors-permanent-latest-signal-of-stability-for-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMAKING CENTER DIRECTORS PERMANENT LATEST SIGNAL OF STABILITY FOR FDA‘Acting’ no more: HHS signals intent to maintain current direction with appointments of Davis, MikhailTue, 08 Sep 2026 17:10:54 -0700https://www.biocentury.com/article/660730/gsk-takes-rights-to-hutchmed-s-kras-antibody-conjugate-deals-reporthttps://www.biocentury.com/article/660730/gsk-takes-rights-to-hutchmed-s-kras-antibody-conjugate-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSGSK TAKES RIGHTS TO HUTCHMED’S KRAS-ANTIBODY CONJUGATE: DEALS REPORTPlus: Alteogen’s latest deal for delivery tech is with Novartis; Menarini in-licenses local rights to Gan & Lee obesity program; and moreTue, 08 Sep 2026 16:28:35 -0700https://www.biocentury.com/article/660662/cloverleaf-turning-5-fu-s-overlooked-rna-mechanism-into-a-new-payloadhttps://www.biocentury.com/article/660662/cloverleaf-turning-5-fu-s-overlooked-rna-mechanism-into-a-new-payload?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILECLOVERLEAF: TURNING 5-FU’S OVERLOOKED RNA MECHANISM INTO A NEW PAYLOADYale spinout lands a $33M pharma-backed seed round to develop antibody conjugates carrying engineered tRNA payloadsTue, 08 Sep 2026 14:55:34 -0700https://www.biocentury.com/article/660719/gan-lee-s-first-big-cross-border-deal-aids-menarini-push-into-obesityhttps://www.biocentury.com/article/660719/gan-lee-s-first-big-cross-border-deal-aids-menarini-push-into-obesity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSGAN & LEE’S FIRST BIG CROSS-BORDER DEAL AIDS MENARINI PUSH INTO OBESITYData for twice-monthly GLP-1R agonist were competitive vs. market leaders Zepbound and WegovyFri, 04 Sep 2026 18:21:46 -0700https://www.biocentury.com/article/660715/six-first-in-class-approvals-in-augusthttps://www.biocentury.com/article/660715/six-first-in-class-approvals-in-august?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTESIX FIRST-IN-CLASS APPROVALS IN AUGUSTEarly September approvals include Ionis’ Zanvastro for Alexander disease, AZ’s Etcamah for breast cancer  Fri, 04 Sep 2026 18:19:28 -0700https://www.biocentury.com/article/660691/pharma-deals-embracing-disruptive-technologieshttps://www.biocentury.com/article/660691/pharma-deals-embracing-disruptive-technologies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSPHARMA DEALS: EMBRACING DISRUPTIVE TECHNOLOGIESDeals by 21 top pharmas in 2H25-1H26 cluster in breakthrough new technologiesFri, 04 Sep 2026 18:14:35 -0700https://www.biocentury.com/article/660717/superluminal-s-60m-series-b-to-drive-first-clinical-study-finance-reporthttps://www.biocentury.com/article/660717/superluminal-s-60m-series-b-to-drive-first-clinical-study-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCESUPERLUMINAL’S $60M SERIES B TO DRIVE FIRST CLINICAL STUDY: FINANCE REPORTPlus: Gene insertion company Typewriter launches with series A; Electra files for NASDAQ listing; and moreFri, 04 Sep 2026 18:07:41 -0700https://www.biocentury.com/article/660721/newly-public-latigo-eikon-each-tap-new-execshttps://www.biocentury.com/article/660721/newly-public-latigo-eikon-each-tap-new-execs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSNEWLY PUBLIC LATIGO, EIKON EACH TAP NEW EXECSPlus: C-suite changes at Allogene, LB Pharma and moreFri, 04 Sep 2026 14:24:33 -0700https://www.biocentury.com/article/660697/beyond-the-genome-regeneron-s-abecasis-on-scaling-drug-discovery-with-genetic-datahttps://www.biocentury.com/article/660697/beyond-the-genome-regeneron-s-abecasis-on-scaling-drug-discovery-with-genetic-data?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONBEYOND THE GENOME: REGENERON’S ABECASIS ON SCALING DRUG DISCOVERY WITH GENETIC DATAThe BioCentury Show: Target discovery outpaces data size at the Regeneron Genetics CenterThu, 03 Sep 2026 18:24:08 -0700https://www.biocentury.com/article/660677/ultragenyx-alumis-look-ahead-after-late-stage-losseshttps://www.biocentury.com/article/660677/ultragenyx-alumis-look-ahead-after-late-stage-losses?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTULTRAGENYX, ALUMIS LOOK AHEAD AFTER LATE-STAGE LOSSESPlus: Moderna, Arrowhead and more in BioCentury’s Clinical Report for Aug 18 – Sept 3Thu, 03 Sep 2026 18:21:54 -0700https://www.biocentury.com/article/660712/remembering-peter-barton-hutt-an-icon-of-fda-lawhttps://www.biocentury.com/article/660712/remembering-peter-barton-hutt-an-icon-of-fda-law?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWREMEMBERING PETER BARTON HUTT, AN ICON OF FDA LAWHutt shaped FDA’s approach to the law in the 1970s, helped craft food and drug law for decades, and made the law come alive for thousands of studentsThu, 03 Sep 2026 13:30:05 -0700https://www.biocentury.com/article/660710/mfn-carve-outs-come-into-focushttps://www.biocentury.com/article/660710/mfn-carve-outs-come-into-focus?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWMFN CARVE-OUTS COME INTO FOCUSBridgeBio says its orphan-only drugs will excluded from its MFN commitment, Incyte hints at exclusionsThu, 03 Sep 2026 13:06:13 -0700https://www.biocentury.com/article/660617/k2-therapeutics-spreading-bets-across-range-of-asia-sourced-assetshttps://www.biocentury.com/article/660617/k2-therapeutics-spreading-bets-across-range-of-asia-sourced-assets?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEK2 THERAPEUTICS: SPREADING BETS ACROSS RANGE OF ASIA-SOURCED ASSETSFormer Legend CEO Ying Huang looks to $250M series A while aiming to replicate an Asia-to-global playbook across a diversified asset portfolioWed, 02 Sep 2026 17:02:21 -0700https://www.biocentury.com/article/660663/will-overton-be-a-heat-shield-or-a-conduit-for-political-and-ideological-influencehttps://www.biocentury.com/article/660663/will-overton-be-a-heat-shield-or-a-conduit-for-political-and-ideological-influence?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYWILL OVERTON BE A HEAT SHIELD OR A CONDUIT FOR POLITICAL AND IDEOLOGICAL INFLUENCE?The answer to that question will determine FDA’s futureWed, 02 Sep 2026 15:00:13 -0700https://www.biocentury.com/article/660682/ada-yonath-ribosome-pioneer-and-nobel-winner-passes-awayhttps://www.biocentury.com/article/660682/ada-yonath-ribosome-pioneer-and-nobel-winner-passes-away?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSADA YONATH, RIBOSOME PIONEER AND NOBEL WINNER, PASSES AWAYTrailblazing Weizmann Institute professor’s work contributed to understanding of antibiotics Wed, 02 Sep 2026 14:32:57 -0700https://www.biocentury.com/article/660666/tyk2-inhibitor-miss-pushes-alumis-toward-precision-strategy-for-lupushttps://www.biocentury.com/article/660666/tyk2-inhibitor-miss-pushes-alumis-toward-precision-strategy-for-lupus?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTYK2 INHIBITOR MISS PUSHES ALUMIS TOWARD PRECISION STRATEGY FOR LUPUSSubgroup signal suggests IFN enrichment could rescue envudeucitinib’s Phase II all-comers miss — a strategy lupus trials have pursued in the pastTue, 01 Sep 2026 18:09:09 -0700https://www.biocentury.com/article/660634/the-war-of-the-claudes-is-coming-for-the-rooms-where-medicines-get-madehttps://www.biocentury.com/article/660634/the-war-of-the-claudes-is-coming-for-the-rooms-where-medicines-get-made?utm_source=bc_rss&utm_medium=rssBIOCENTURY | GUEST COMMENTARYTHE WAR OF THE CLAUDES IS COMING FOR THE ROOMS WHERE MEDICINES GET MADE To safely scale drug development, AI must strengthen teams, make decisions auditable, and build human expertise rather than bypass itTue, 01 Sep 2026 17:43:25 -0700https://www.biocentury.com/article/660667/what-car-t-s-new-safety-concern-could-mean-for-immune-reset-competitionhttps://www.biocentury.com/article/660667/what-car-t-s-new-safety-concern-could-mean-for-immune-reset-competition?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTWHAT CAR T’S NEW SAFETY CONCERN COULD MEAN FOR IMMUNE RESET COMPETITIONNovartis discloses three autoimmune disease patient deaths after CAR T cell therapyTue, 01 Sep 2026 17:09:55 -0700https://www.biocentury.com/article/660670/new-roles-at-vertex-amid-crinetics-integrationhttps://www.biocentury.com/article/660670/new-roles-at-vertex-amid-crinetics-integration?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSNEW ROLES AT VERTEX AMID CRINETICS INTEGRATIONPlus: Invivyd taps a permanent CEO; and moreTue, 01 Sep 2026 14:08:02 -0700https://www.biocentury.com/article/660655/mfn-deals-lilly-takeout-fda-pick-overton-a-biocentury-podcasthttps://www.biocentury.com/article/660655/mfn-deals-lilly-takeout-fda-pick-overton-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWMFN DEALS, LILLY TAKEOUT, FDA PICK OVERTON — A BIOCENTURY PODCASTMonday’s drug pricing reveal by White House short on U.S. biopharmasMon, 31 Aug 2026 18:38:55 -0700https://www.biocentury.com/article/660659/white-house-fails-to-bring-mid-tier-biotechs-to-mfn-tablehttps://www.biocentury.com/article/660659/white-house-fails-to-bring-mid-tier-biotechs-to-mfn-table?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWHITE HOUSE FAILS TO BRING MID-TIER BIOTECHS TO MFN TABLEContrary to administration leaks, high-profile mid-sized biotechs were conspicuous by their absence at a White House press conferenceMon, 31 Aug 2026 17:52:50 -0700https://www.biocentury.com/article/660654/lilly-s-deal-spree-continues-with-merida-takeout-deals-reporthttps://www.biocentury.com/article/660654/lilly-s-deal-spree-continues-with-merida-takeout-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSLILLY’S DEAL SPREE CONTINUES WITH MERIDA TAKEOUT: DEALS REPORTHaisco, Duality feature in cross-border deals; and moreMon, 31 Aug 2026 17:17:19 -0700https://www.biocentury.com/article/660638/can-silencers-add-benefit-in-attr-cmhttps://www.biocentury.com/article/660638/can-silencers-add-benefit-in-attr-cm?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTCAN SILENCERS ADD BENEFIT IN ATTR-CM?Detailed data from Phase III CARDIO-TTRansform trial of eplontersen from AZ/Ionis raise more questionsFri, 28 Aug 2026 16:35:05 -0700https://www.biocentury.com/article/660644/mid-sized-biotechs-pressured-to-accept-mfn-deals-crafted-for-big-pharmahttps://www.biocentury.com/article/660644/mid-sized-biotechs-pressured-to-accept-mfn-deals-crafted-for-big-pharma?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWMID-SIZED BIOTECHS PRESSURED TO ACCEPT MFN DEALS CRAFTED FOR BIG PHARMAComplex calculus centering on payer mix and tariff exposure underpins decisions to make most-favored nation pricing dealsFri, 28 Aug 2026 16:25:12 -0700https://www.biocentury.com/article/660640/trans-pacific-ausperbio-draws-120m-to-advance-aso-for-chronic-hbv-finance-reporthttps://www.biocentury.com/article/660640/trans-pacific-ausperbio-draws-120m-to-advance-aso-for-chronic-hbv-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCETRANS-PACIFIC AUSPERBIO DRAWS $120M TO ADVANCE ASO FOR CHRONIC HBV: FINANCE REPORTPlus: Population Health, Arch launch Asia-to-West NewCo Sentivera with Haisco program, and moreFri, 28 Aug 2026 16:17:47 -0700https://www.biocentury.com/article/660629/the-global-fih-trials-race-a-back-to-school-podcast-specialhttps://www.biocentury.com/article/660629/the-global-fih-trials-race-a-back-to-school-podcast-special?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTHE GLOBAL FIH TRIALS RACE, A BACK TO SCHOOL PODCAST SPECIAL Back to School 2026: The bold risks required to overhaul first-in-human studies around the worldThu, 27 Aug 2026 17:06:45 -0700https://www.biocentury.com/article/660560/kynexis-lowering-kynurenic-acid-levels-to-improve-cognitive-functionhttps://www.biocentury.com/article/660560/kynexis-lowering-kynurenic-acid-levels-to-improve-cognitive-function?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEKYNEXIS: LOWERING KYNURENIC ACID LEVELS TO IMPROVE COGNITIVE FUNCTION Dutch biotech’s KAT2 inhibitor for cognitive impairment associated with schizophrenia is backed by nine-figure series AThu, 27 Aug 2026 16:28:54 -0700https://www.biocentury.com/article/660624/at-least-nine-pdufa-dates-on-fda-s-september-dockethttps://www.biocentury.com/article/660624/at-least-nine-pdufa-dates-on-fda-s-september-docket?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEAT LEAST NINE PDUFA DATES ON FDA’S SEPTEMBER DOCKETFour new therapeutics up for orphan indicationsThu, 27 Aug 2026 13:15:05 -0700https://www.biocentury.com/article/660618/revmed-s-first-in-class-pancreatic-therapy-among-fastest-cnpv-approvalshttps://www.biocentury.com/article/660618/revmed-s-first-in-class-pancreatic-therapy-among-fastest-cnpv-approvals?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONREVMED’S FIRST-IN-CLASS PANCREATIC THERAPY AMONG FASTEST CNPV APPROVALS Rasonque daraxonrasib is first new cancer drug under FDA’s pilot programWed, 26 Aug 2026 17:02:12 -0700https://www.biocentury.com/article/660615/science-spotlight-microbiome-biomarkers-show-promise-in-gi-cancerhttps://www.biocentury.com/article/660615/science-spotlight-microbiome-biomarkers-show-promise-in-gi-cancer?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: MICROBIOME BIOMARKERS SHOW PROMISE IN GI CANCERBioCentury's translational roundup also includes newly identified immune hubs in the skull and a stem cell model of endometriosisWed, 26 Aug 2026 16:01:17 -0700https://www.biocentury.com/article/660401/how-fast-can-first-in-human-trials-move-molnupiravir-set-16-week-benchmarkhttps://www.biocentury.com/article/660401/how-fast-can-first-in-human-trials-move-molnupiravir-set-16-week-benchmark?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONHOW FAST CAN FIRST-IN-HUMAN TRIALS MOVE? MOLNUPIRAVIR SET 16-WEEK BENCHMARKThe COVID-19 program compressed a process estimated to take 46 weeks by eliminating white space across regulatory review, trial start-up and executionWed, 26 Aug 2026 15:37:45 -0700https://www.biocentury.com/article/660613/with-biohaven-deal-sk-biopharma-builds-epilepsy-franchise-takes-step-toward-big-biotechhttps://www.biocentury.com/article/660613/with-biohaven-deal-sk-biopharma-builds-epilepsy-franchise-takes-step-toward-big-biotech?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSWITH BIOHAVEN DEAL, SK BIOPHARMA BUILDS EPILEPSY FRANCHISE, TAKES STEP TOWARD ‘BIG BIOTECH’Korean company adds late-stage seizure therapy behind growth product Xcopri, refreshing Biohaven’s balance sheetWed, 26 Aug 2026 12:17:30 -0700https://www.biocentury.com/article/660606/pilkington-departs-hsbc-for-natwest-s-new-venture-teamhttps://www.biocentury.com/article/660606/pilkington-departs-hsbc-for-natwest-s-new-venture-team?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSPILKINGTON DEPARTS HSBC FOR NATWEST’S NEW VENTURE TEAMPlus: Arcutis vet Todd Edwards joins Oruka to lead commercial Tue, 25 Aug 2026 18:02:25 -0700https://www.biocentury.com/article/660603/nyu-physician-scientist-traces-oxygen-metabolism-to-pediatric-disease-breakthroughhttps://www.biocentury.com/article/660603/nyu-physician-scientist-traces-oxygen-metabolism-to-pediatric-disease-breakthrough?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONNYU PHYSICIAN-SCIENTIST TRACES OXYGEN METABOLISM TO PEDIATRIC DISEASE BREAKTHROUGHPacold’s Trailblazer Prize-winning research on hypoxic tumor metabolism yielded a therapy for a rare mitochondrial diseaseTue, 25 Aug 2026 16:52:26 -0700https://www.biocentury.com/article/660488/federated-learning-requires-more-than-big-tech-infrastructurehttps://www.biocentury.com/article/660488/federated-learning-requires-more-than-big-tech-infrastructure?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFEDERATED LEARNING REQUIRES MORE THAN BIG TECH INFRASTRUCTUREAmazon and Nvidia provide essential building blocks, while orchestration layers and workbench integrations turn them into networks R&D can useTue, 25 Aug 2026 13:00:44 -0700https://www.biocentury.com/article/660596/moderna-vaccine-genentech-obesity-deal-trump-s-fda-pick-a-biocentury-podcasthttps://www.biocentury.com/article/660596/moderna-vaccine-genentech-obesity-deal-trump-s-fda-pick-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMODERNA VACCINE, GENENTECH OBESITY DEAL, TRUMP’S FDA PICK — A BIOCENTURY PODCASTA Phase III melanoma win gives Moderna and Merck important validation for mRNA neoantigen vaccines; Genentech partners with Hanmi; Heidi Overton on deck for FDAMon, 24 Aug 2026 18:22:17 -0700